Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tracy Murphy

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Leukemia|August 23, 2019
Cryptic genomic lesions in adverse-risk acute myeloid leukemia identified by integrated whole genome and transcriptome sequencingJaeseung C Kim, Philip C Zuzarte, Tracy Murphy, et al.
Blood|August 26, 2025
Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemiaCristiana O'Brien, Nirvana Nursimulu, Anit Tyagi, et al.
Haematologica|January 4, 2020
Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemiaRobert Puckrin, Eshetu G Atenafu, Jaime O Claudio, et al.
Nature Communications|February 14, 2026
Blood-based epigenetic instability linked to human aging and diseaseSalman Basrai, Ido Nofech-Mozes, Rajesh Detroja, et al.
Science Advances|December 10, 2020
Integration of intra-sample contextual error modeling for improved detection of somatic mutations from deep sequencingSagi Abelson, Andy G X Zeng, Ido Nofech-Mozes, et al.
Current Oncology (Toronto, Ont.)|March 11, 2021
Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL RegimenRuiqi Chen, Xing Liu, Arjun D Law, et al.
British Journal of Haematology|May 13, 2020
Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapyHassan Sibai, Ruiqi Chen, Xing Liu, et al.
Haematologica|June 22, 2023
Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemiaTracy Murphy, Jinfeng Zou, Andrea Arruda, et al.
European Journal of Haematology|February 2, 2023
Mutational profile, outcomes, and impact of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia and inconclusive cytogenetic analysisRam Vasudevan Nampoothiri, Kenny Tang, Andre Schuh, et al.
The Lancet. Haematology|October 11, 2025
Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trialGuillaume Richard-Carpentier, Gopila Gupta, Charina Koraksic, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Leukemia|August 23, 2019
Cryptic genomic lesions in adverse-risk acute myeloid leukemia identified by integrated whole genome and transcriptome sequencingJaeseung C Kim, Philip C Zuzarte, Tracy Murphy, et al.
Blood|August 26, 2025
Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemiaCristiana O'Brien, Nirvana Nursimulu, Anit Tyagi, et al.
Haematologica|January 4, 2020
Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemiaRobert Puckrin, Eshetu G Atenafu, Jaime O Claudio, et al.
Nature Communications|February 14, 2026
Blood-based epigenetic instability linked to human aging and diseaseSalman Basrai, Ido Nofech-Mozes, Rajesh Detroja, et al.
Science Advances|December 10, 2020
Integration of intra-sample contextual error modeling for improved detection of somatic mutations from deep sequencingSagi Abelson, Andy G X Zeng, Ido Nofech-Mozes, et al.
Current Oncology (Toronto, Ont.)|March 11, 2021
Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL RegimenRuiqi Chen, Xing Liu, Arjun D Law, et al.
British Journal of Haematology|May 13, 2020
Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapyHassan Sibai, Ruiqi Chen, Xing Liu, et al.
Haematologica|June 22, 2023
Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemiaTracy Murphy, Jinfeng Zou, Andrea Arruda, et al.
European Journal of Haematology|February 2, 2023
Mutational profile, outcomes, and impact of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia and inconclusive cytogenetic analysisRam Vasudevan Nampoothiri, Kenny Tang, Andre Schuh, et al.
The Lancet. Haematology|October 11, 2025
Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trialGuillaume Richard-Carpentier, Gopila Gupta, Charina Koraksic, et al.
Pageof 4